Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Kura Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Exelixis
University of Kansas Medical Center
Exelixis
Bristol-Myers Squibb
SCRI Development Innovations, LLC
Calithera Biosciences, Inc
Augusta University
University of Pittsburgh
National Cancer Institute (NCI)
Fondazione Ricerca Traslazionale